Sutent (sunitinib)

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

c-KIT inhibitor, PDGFR inhibitor, VEGFR inhibitor

Related drugs:

SDHB deletion	Gastrointestinal Stromal Tumor	SDHB deletion	Gastrointestinal Stromal Tumor	sunitinib Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) sunitinib Sensitive : A2 NCCN - 2wk	sunitinib Sensitive: A2 - Guideline NCCN - 2 weeks sunitinib Sensitive : A2 NCCN - 2 weeks - (New A2)
ABCG2 expression	Colorectal Cancer	ABCG2 expression	Colorectal Cancer	sunitinib + GF120918 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) sunitinib + GF120918 Sensitive : D AACR 2023 - 2wk	sunitinib + GF120918 Sensitive: D – Preclinical AACR 2023 - 2 weeks sunitinib + GF120918 Sensitive : D AACR 2023 - 2 weeks - (New D)
ABCB1 expression	Colorectal Cancer	ABCB1 expression	Colorectal Cancer	sunitinib + GF120918 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) sunitinib + GF120918 Sensitive : D AACR 2023 - 2wk	sunitinib + GF120918 Sensitive: D – Preclinical AACR 2023 - 2 weeks sunitinib + GF120918 Sensitive : D AACR 2023 - 2 weeks - (New D)
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
KIT mutation	Thymic Carcinoma	KIT mutation	Thymic Carcinoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Meningioma	No biomarker	Meningioma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
KIT exon 11 mutation	Melanoma	KIT exon 11 mutation	Melanoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
KIT exon 13 mutation	Melanoma	KIT exon 13 mutation	Melanoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	sunitinib Resistant: A2 - Guideline sunitinib Resistant : A2	sunitinib Resistant: A2 - Guideline sunitinib Resistant : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
ARID1A mutation	Renal Cell Carcinoma	ARID1A mutation	Renal Cell Carcinoma	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B
MTOR mutation	Renal Cell Carcinoma	MTOR mutation	Renal Cell Carcinoma	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B
ROBO3 mutation	Renal Cell Carcinoma	ROBO3 mutation	Renal Cell Carcinoma	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B
FLT1 rs9554320	Renal Cell Carcinoma	FLT1 rs9554320	Renal Cell Carcinoma	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B
KDR rs2071559	Renal Cell Carcinoma	KDR rs2071559	Renal Cell Carcinoma	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
KIT mutation	Melanoma	KIT mutation	Melanoma	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	sunitinib + PLX9486 Sensitive: C3 – Early Trials sunitinib + PLX9486 Sensitive : C3	sunitinib + PLX9486 Sensitive: C3 – Early Trials sunitinib + PLX9486 Sensitive : C3
TAF15-NR4A3 fusion	Soft Tissue Sarcoma	TAF15-NR4A3 fusion	Soft Tissue Sarcoma	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3
EWSR1-NR4A3 fusion	Soft Tissue Sarcoma	EWSR1-NR4A3 fusion	Soft Tissue Sarcoma	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
PD-1 elevation	Renal Cell Carcinoma	PD-1 elevation	Renal Cell Carcinoma	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3
HMOX1 expression	Clear Cell Renal Cell Carcinoma	HMOX1 expression	Clear Cell Renal Cell Carcinoma	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
FLT3 G846S	Acute Myelogenous Leukemia	FLT3 G846S	Acute Myelogenous Leukemia	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3

Sutent (sunitinib)

Associations
(131)

Associations
(131)

Sutent (sunitinib)

Associations(131)

Associations(131)

Associations
(131)

Associations
(131)